Webinars

For healthcare professionals

Sign up to be notified for future webinars.

This form is for healthcare professionals practicing in the United States only. If you are a patient looking for more information, click here

indicates a required field.

*
This field is required.
*
This field is required.
This field is required.
This field is required.
*
This field is required.
*
This field is required.
*
This field is required.
*
This field is required.
*
This field is required.
This field is required.

This form is only for healthcare professionals practicing in United States.

Thank you!

We’ve received your request – we’ll be in touch with product information soon.

Oops!

Something went wrong. Please try again later.

Upcoming webinars

Check back soon for more upcoming webinars.

On-demand webinars

MiniMedTM 780G system
Expanding indications - A deep dive into insulin-requiring type 2 diabetes with the MiniMedTM 780G system

This livestream focused on expanding indications of the MiniMedTM 780G system and its potential to revolutionize diabetes management for individuals with insulin-requiring type 2 diabetes.  Learn about the latest clinical data, real-world applications, and patient success stories that highlight the benefits of this innovative approach to managing a traditionally complex condition.

Life with diabetes just got easier - introducing new sensors

This livestream focused on how the MiniMed™ 780G system coupled with the 7-day infusion set and new sensors continues to make life with diabetes easier. Learn about the sensor differences, ordering updates and hear from leading experts in the field.

Strategies to reduce diabetes burden - Part 1

This webinar explored the reciprocal relationship between mental health and glycemic outcomes and how AID can help to reduce burden.

Strategies to reduce diabetes burden - Part 2

This webinar reviewed how carb counting, bolus timing, and missed boluses can be simplified with automated insulin delivery.

Looking Beyond the Usual Suspects

Take a look beyond the usual suspects when considering who is a candidate for the MiniMed™ 780G system. This webinar reviewed the ongoing clinical evidence that supports AID.

The power of the MiniMed™ 780G system

This webinar discussed how MiniMed™ 780G system algorithm works, through case study examples.

Talking to your patients about automated insulin delivery

This webinar shared the healthcare provider perspective on navigating choice conversations, talking about the system, and practical tips for users.

A simplified approach to optimizing therapy

This webinar will reviewed the simple approach to managing and optimizing therapy on the MiniMed™ 780G system.

The MiniMed™ 780G system in action

This webinar covered the interpretations methodology, key behaviors and settings that impact outcomes, and considerations, such as exercise and sick days.

Type 2 diabetes
Managing type 2 diabetes just got easier

This webinar discussed how the MiniMed™ 780G system and the InPen system help reduce the burden of decision-making, impact glycemic outcomes, and enhance quality of life for people living with type 2 diabetes.

This presentation is provided for general educational purposes only and should not be considered the exclusive source for this type of information. At all times, it is the professional responsibility of the practitioner to exercise independent clinical judgment in a particular situation. Changes in a patient’s disease and/or medications may alter the efficacy the therapy or product features and results vary.

Important Safety Information: MiniMedTM 780G system with SmartGuardTM technology with Instinct sensor, Simplera SyncTM sensor, and GuardianTM 4 sensor

The MiniMedTM 780G system is intended for the continuous delivery of basal insulin at selectable rates and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose vales in the fluid under the skin.

The MiniMedTM 780G System includes SmartGuardTM technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values. The system is intended for use with connected sensors, including the Simplera SyncTM and GuardianTM 4 sensors and integrated continuous glucose monitors, including the Instinct sensor, each of which has different wear-time, form factor, insertion site, and other distinguishing characteristics that relate to sensor performance. Consult the appropriate sensor user guide when using the system. Discuss treatment decisions with your HCP.

WARNING: Do not use the SmartGuardTM feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuardTM feature.

WARNING: Do not use MiniMedTM 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of MiniMedTM 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuardTM feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including user guides and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, see https://bit.ly/MiniMedRisks.

©2026 MiniMed. MiniMed and MiniMed logo are trademarks of Medtronic MiniMed, Inc. The sensor shape and appearance, Abbott, and “a” logo are marks and/or designs of the Abbott group of companies in various territories and used under license. Sensor image ©2026 Abbott. TM*Third–party brands are trademarks of their respective owners.

DreaMed Diabetes is a trademark of DreaMed Diabetes, Ltd. The MiniMedTM 780G system algorithm includes technology developed by DreaMed Diabetes.